LGC Acquires Bioanalytical Sciences Business from Quotient Bioresearch
LGC
and
Quotient Bioresearch
are pleased to announce that they have reached agreement on the sale by Quotient of its Bioanalytical Sciences division to LGC.
Quotient Bioanalytical Sciences is a leading provider of bioanalytical services across the fields of small molecules, biomarkers, biopharmaceuticals and microbiological testing to customers in the pharmaceutical and biotechnology sectors. It is based at Fordham, Cambridgeshire.
The acquisition, which will form part of LGC’s Health Sciences division, will enable LGC to provide an enhanced range of products and services to the pharmaceutical sector including bioanalysis, materials science and reference materials amongst others.
Under the terms of the transaction, Quotient and LGC have committed to collaborate as preferred partners on the provision of Bioanalytical Sciences. This will enable clients to continue to benefit from the early development services offered by the Quotient group including clinical trials, metabolism and radiolabelling. The Bioanalytical Sciences business will continue to trade using the “Quotient” name under its new ownership for the time being.
The transaction follows the sale two years ago by Quotient to LGC of HFL Sport Science, which is also based at the Fordham site.
Jeremy Cook, Managing Director of LGC’s Health Sciences said, “We’re delighted to have acquired Quotient Bioanalytical Sciences, a high quality business which is complementary to our existing activities. We continue to develop our range of first-rate services in the pharmaceutical, biotechnology and agrochemical sectors by offering our customers a unique mix of technical experience, leading edge facilities and knowledgeable people.”
Dr Steve Pleasance, Managing Director of Quotient Bioanalytical Sciences said “LGC’s focus on complex analytical chemistry, high quality science and service delivery make them a natural home for our business. Both our organisations have reputations built upon quality and innovation and LGC’s global presence will help support the continued growth of services to our customers.”
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
